Table 2

Associations between ERCC1 expression and clinical characteristics in groups with or without adjuvant chemotherapy
Characteristic Adjuvant chemotherapy (n = 57) No adjuvant chemotherapy (n = 36) Total (n = 93)
ERCC1 (+) (n = 34) ERCC1 (−) (n = 23) P ERCC1 (+) (n = 20) ERCC1 (−) (n = 16) P ERCC1 (+) (n = 54) ERCC1 (−) (n = 39) P
Sex 0.49 0.19 0.21
Men 29 (85.3%) 18 (78.3%) 19 (95.0%) 13 (81.3%) 48 (88.9%) 31 (79.5%)
Women 5 (14.7%) 5 (21.7%) 1 (5.0%) 3 (18.8%) 6 (11.1%) 8 (20.5%)
Age at operation 0.35 0.24 0.92
≥ 65 years 8 (23.5%) 8 (34.8%) 15 (75.0%) 9 (56.3%) 23 (42.6%) 17 (43.6%)
< 65 years 26 (76.5%) 15 (65.2%) 5 (25.0%) 7 (43.8%) 31 (57.4%) 22 (56.4%)
T stage 0.68 0.65 0.99
T1-T2 2 (5.9%) 2 (8.7%) 9 (45.0%) 6 (37.5%) 11 (20.4%) 8 (20.5%)
T3-T4 32 (94.1%) 21 (91.3%) 11 (55.0%) 10 (62.5%) 43 (79.6%) 31 (79.5%)
N stage 0.48 0.58 0.13
Node negative 16 (47.1%) 13 (56.5%) 16 (80.0%) 16 (100%) 32 (59.3%) 29 (74.4%)
Node positive 18 (52.9%) 10 (43.5%) 4 (20.0%) 0 (0%) 22 (40.7%) 10 (25.6%)
Histologic type 0.64 0.87 0.69
Squamous differentiation
6 (17.6%) 3 (13.0%) 1 (5.0%) 1 (6.3%) 7 (13.0%) 4 (10.3%)
Other types 28 (82.4%) 20 (87.0%) 19 (95.0%) 15 (93.8%) 47 (87.0%) 35 (89.7%)
Pathologic grade* 0.74 0.69 0.22
Grade 2 2 (5.9%)

5

(21.7%)

2

(10.0%)

1 (6.3%)

6

4 (7.4%)

(15.4%)
Grade 3 32 (94.1%) 18 (78.3%) 18 (90.0%) 15 (93.8%) 50 (92.6%) 33 (84.6%)

*1973 WHO grading.

Sun et al.

Sun et al. BMC Cancer 2012 12:187   doi:10.1186/1471-2407-12-187

Open Data